Clinical Trial Update: A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease [Phase 3]

View source ↗

Summary

The Phase 3 study of Mongersen (GED-0301) for active Crohn's disease has been withdrawn by the sponsor Celgene.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mongersen (GED-0301)

Snippet

Sponsor: Celgene | Conditions: Crohn Disease | Phase 3 | Status: WITHDRAWN